Printable version 
COMING SOON!
Later this year, the Enterprise will launch HIV ePrints, an open-access repository of HIV vaccine research and development publications to enable faster and more open communication of the latest results, hypotheses, and ideas.
HIV ePrints will allow anyone to search for and download the latest papers, book chapters, and other documents that would not be available without a subscription or only become available after an embargo period.
Help Stimulate and Accelerate Research!
Faster and more open access to scientific literature helps stimulate and accelerate research. However, a recent study (Voronin et al., PLoS ONE, 2010) found that among newly published papers in the HIV vaccine field, only 20% were openly available, while 80% required a subscription for access.
However, authors can make their manuscripts openly available as postprints (author-generated final versions/post-refereeing of their papers) at any time in open-access repositories, like HIV ePrints.
How You Can Support Open Access
- Make your manuscripts openly available as postprints in your institution’s repositories
- Work with the Enterprise! We are compiling literature for HIV ePrints, our open access repository for the HIV vaccine community
- Send us the postprint version of your papers today to be accessible on HIV ePrints later this year, hiveprints@vaccineenterprise.org.
- Learn More about Open Access to scientific literature
Yes. Copyright transfer agreements of Science, the Lancet, Blood, PNAS, Journal of Virology and many others allow authors to legally deposit postprint versions of their papers in open-access repositories.
